Palvella Therapeutics: Engaging Investors with Key Presentations
Palvella Therapeutics, Inc. (Nasdaq: PVLA), a pioneering biopharmaceutical firm, has announced its participation in upcoming healthcare investor conferences that promise to shed light on its groundbreaking work. With a mission to develop and offer innovative therapies for patients affected by serious, rare genetic skin diseases, Palvella is at the forefront of medical advancements in this specialized area.
Upcoming Conference Details
The company's Chief Executive Officer, Wes Kaupinen, will be representing Palvella at two significant conferences. These events are crucial for illustrating the company’s progress and commitment to patient care. Details of the presentations are:
Cantor Global Healthcare Conference
This event is set for Thursday, September 4, with the presentation scheduled for 2:45 PM ET. It's a prime opportunity for investors and stakeholders to gain insights into Palvella's strategic initiatives.
H.C. Wainwright 27th Annual Global Investment Conference
Taking place on Monday, September 8 at 10:30 AM ET, this prestigious conference will further highlight Palvella’s ongoing commitment to innovation in healthcare and its focus on rare diseases.
Accessing Live Broadcasts
For those unable to attend in person, live webcasts of both presentations will be accessible through the Events and Presentations section of Palvella's official website. Additionally, a recorded version will be available for 90 days post-event, ensuring that interested individuals can stay updated on Palvella's advancements.
About Palvella Therapeutics
Palvella Therapeutics is a dedicated clinical-stage biopharmaceutical company, founded by experts in rare disease drug development. The firm is intensely focused on the creation of novel therapies, particularly in addressing severe genetic skin diseases that currently lack FDA-approved treatment options. Utilizing its sophisticated QTORIN™ platform, Palvella is actively developing a range of innovative product candidates aimed at improving the lives of those afflicted by these challenging conditions.
One of its leading candidates, the QTORIN™ 3.9% rapamycin anhydrous gel (commonly referred to as QTORIN™ rapamycin), is making headlines as it embarks on pivotal clinical trials. This promising treatment is currently being evaluated in the Phase 3 SELVA clinical trial aimed at microcystic lymphatic malformations, as well as the Phase 2 TOIVA clinical trial focused on cutaneous venous malformations.
Future Directions and Commitment to Patients
As Palvella Therapeutics prepares for these important presentations, it celebrates its ongoing endeavors to bring crucial treatments to market. The company’s robust pipeline and dedication to patient-focused solutions position it as a key player in the biopharmaceutical industry. With its groundbreaking QTORIN™ platform, Palvella is excited to pave the way for future advancements that will not only enhance patient outcomes but also enrich the lives of those suffering from rare skin diseases.
Contact Information
Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com
Media
Marcy Nanus
Managing Partner, Trilon Advisors, LLC
mnanus@trilonadvisors.com
Frequently Asked Questions
What is the focus of Palvella Therapeutics?
Palvella Therapeutics focuses on developing therapies for serious, rare genetic skin diseases lacking FDA-approved treatments.
When will the presentations take place?
The presentations will occur on September 4 and September 8.
How can investors access the presentations?
Investors can access the live webcasts on Palvella's website and view archived versions thereafter.
What is QTORIN™ rapamycin?
QTORIN™ rapamycin is Palvella's lead product candidate, currently under evaluation in clinical trials for treating rare skin diseases.
Who can be contacted for more information?
Wesley H. Kaupinen is the point of contact for investor inquiries, while Marcy Nanus can be reached for media relations.
